Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.70 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.64 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.64 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | PRCP | P42785 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377246 | 0.94 | NAAA (0.79) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL12650953 | 0.92 | NAAA (0.62) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL19093034 | 0.92 | NAAA (0.62) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL1678750 | 0.92 | NAAA (0.83) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL8690057 | 0.92 | NAAA (0.77) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL2736687 | 0.92 | NAAA (0.83) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL9511929 | 0.92 | NAAA (0.83) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL2639022 | 0.90 | NAAA (0.86) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL6359440 | 0.90 | NAAA (0.86) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL8594845 | 0.89 | NAAA (0.58) | NAAAGNAI3GNAO1GNAI1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906930-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | claimed |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-20 | — | — | US | claimed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | disclosed |
| US-9346808-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-24 | — | — | US | disclosed |
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-7495009-B2 | Imidazopyridine derivatives as melancortin receptor agonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-7495009-B2 | Imidazopyridine derivatives as melancortin receptor agonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-5827863-A | Pyrazole derivatives as angiotensin II antagonists | J. URIACH & CIA, S.A. (ES) | 1998-10-27 | — | — | US | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | NAAA 1045/4885GNAI3 1878/4885GNAO1 2401/4885 |
| US-20160264577-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | NAAA 4643/4885GNAI3 370/4885GNAO1 3328/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | NAAA 3625/4885GNAI3 158/4885GNAO1 1539/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | NAAA 2958/4885GNAI3 232/4885GNAO1 1414/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | NAAA 2965/4885GNAI3 224/4885GNAO1 1399/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | NAAA 287/4885GNAI3 717/4885GNAO1 143/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | NAAA 3334/4885GNAI3 245/4885GNAO1 1349/4885 |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | HSP90AB1, HSP90AA1, HSP90B1 | NAAA 4519/4885GNAI3 755/4885GNAO1 1858/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | NAAA 2955/4885GNAI3 241/4885GNAO1 1403/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | NAAA 4495/4885GNAI3 2801/4885GNAO1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.